(Q36836263)

16 August 2017

1 reference

title

Opportunities for improving the therapeutic ratio for patients with sarcoma (English)

1 reference

16 August 2017

0 references

Jay S Wunder

1

1 reference

16 August 2017

Torsten O Nielsen

2

1 reference

16 August 2017

Robert G Maki

3

1 reference

16 August 2017

Brian O'Sullivan

4

1 reference

16 August 2017

Benjamin A Alman

5

1 reference

16 August 2017

language of work or name

1 reference

1 June 2007

1 reference

Lancet Oncology Commission

16 August 2017

1 reference

16 August 2017

8

1 reference

16 August 2017

6

1 reference

16 August 2017

513-524

1 reference

Microarray analysis of sarcomas

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

EWS-ETS oncoproteins: the linchpins of Ewing tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Fractures following radiotherapy and limb-salvage surgery for lower extremity soft-tissue sarcomas. A comparison of high-dose and low-dose radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Radiation planning comparison for superficial tissue avoidance in radiotherapy for soft tissue sarcoma of the lower extremity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

The Indications for and the Prognostic Significance of Amputation as the Primary Surgical Procedure for Localized Soft Tissue Sarcoma of the Extremity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Prognostic Factors for Survival in Patients With Locally Recurrent Extremity Soft Tissue Sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Primary soft tissue sarcoma and its local recurrence: genetic changes studied by comparative genomic hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Wound healing morbidity in STS patients treated with preoperative radiotherapy in relation to in vitro skin fibroblast radiosensitivity, proliferative capacity and TGF-β activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Effect of radiation and cell implantation on wound healing in a rat model.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Model of radiation-impaired healing of a deep excisional wound.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Radiation response: an additional unique signature of myxoid liposarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Radiation combined with EGFR signal inhibitors: head and neck cancer focus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Expression of osteopontin and HGF/met in adult soft tissue tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Ifosfamide in the adjuvant therapy of soft tissue sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Cancer pharmacogenetics: polymorphisms, pathways and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Differential sensitivity of liposarcoma subtypes to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Targeting the cell cycle: a new approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

1 reference

7 January 2021

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Malignant peripheral nerve sheath tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Regulation of cancer cell migration and bone metastasis by RANKL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

A mutant PTH/PTHrP type I receptor in enchondromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Targeting the hedgehog signaling pathway with small molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Translating the histone code into leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Side population cells isolated from mesenchymal neoplasms have tumor initiating potential

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Sarcoma derived from cultured mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Folate-linked lipid-based nanoparticle for targeted gene delivery.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Multicolor quantum dots for molecular diagnostics of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Restoration of p53 function leads to tumour regression in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Practical Bayesian adaptive randomisation in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970169-9

7 January 2021

10.1016/S1470-2045(07)70169-9

Identifiers

DOI

1 reference

16 August 2017

1 reference